Eli Lilly将建造3.5B宾夕法尼亚州药物注射厂,到2031年创造2 800个工作机会。 Eli Lilly to build $3.5B Pennsylvania plant for injectable drugs, creating 2,800 jobs by 2031.

Eli Lilly和Co.宣布了一项35亿美元的计划,在宾夕法尼亚州的Fogelsville建造一个制造设施,生产可注射药物,包括仍在研究中的减重治疗重整药。 Eli Lilly and Co. announced a $3.5 billion plan to build a manufacturing facility in Fogelsville, Pennsylvania, to produce injectable drugs, including the weight-loss treatment retatrutide, which is still under study. 建筑工程定于2026年开始,2031年竣工,创造2 800个就业机会,包括850个高价值职位。 Construction is set to begin in 2026 and finish by 2031, creating over 2,800 jobs, including 850 high-value positions. 该项目是美国更广泛扩张的一部分,它支持增加糖尿病和肥胖疗法(如Zepbound和Mounjaro)的生产,这些疗法创造了创纪录的第三季度利润和收入。 The project, part of a broader U.S. expansion, supports increased production of diabetes and obesity therapies like Zepbound and Mounjaro, which drove record third-quarter profits and revenue. 宾夕法尼亚州正在提供高达1亿美元的奖励措施,包括税收抵免和劳动力补助。 Pennsylvania is providing up to $100 million in incentives, including tax credits and workforce grants. 该设施将利用先进技术,在对关键药品的需求不断增长的情况下加强国内制造业。 The facility will use advanced technologies and strengthen domestic manufacturing amid rising demand for key medications.